<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39438926</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1752-1947</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>23</Day></PubDate></JournalIssue><Title>Journal of medical case reports</Title><ISOAbbreviation>J Med Case Rep</ISOAbbreviation></Journal><ArticleTitle>Circadian re-set repairs long-COVID in a prodromal Parkinson's parallel: a case series.</ArticleTitle><Pagination><StartPage>496</StartPage><MedlinePgn>496</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13256-024-04812-9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In this case series, results from daily visual exposure to intense polychromatic light of 2000 to 4000 LUX is presented. Bright light treatment is a standard procedure for treating seasonal affective disorder and prodromal Parkinson's disease with high success. With the post-encephalitic symptoms of long-COVID closely approximating those of prodromal Parkinson's disease, we treated insomnia and sleep-related parameters in these patients, including total sleep, number of awakenings, tendency to fall back to sleep, and fatigue, to determine whether mending sleep could improve quality of life.</AbstractText><AbstractText Label="CASE PRESENTATION" NlmCategory="METHODS">We present three female and two male Caucasian patients aged 42-70 years with long-COVID that persisted from 12 weeks to 139 weeks after contracting coronavirus disease.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">A light presentation protocol was adapted for long-COVID that not only restored sleep in all patients, but also unexpectedly repaired the depression, anxiety, and cognitive changes (brain fog) as well. A robust pattern of recovery commencing 4-5 days after treatment and was maintained for weeks to months without relapse. These preliminary findings represent a novel, minimally invasive approach for managing the most debilitating symptoms of long-COVID, making it an ideal candidate for the drug hypersensitive, post-encephalitic brain. That a compromised circadian mechanism seen in Parkinson's disease may also underlie post-encephalitic long-COVID implicates a compromised role of the circadian system in these disorders.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Willis</LastName><ForeName>Gregory L</ForeName><Initials>GL</Initials><AffiliationInfo><Affiliation>The Bronowski Institute of Behavioural Neuroscience, Woodend, VIC, 3442, Australia. director@bronowski.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Endo</LastName><ForeName>Takuyuki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Osaka Toneyama Medical Center, 5-1-1, Toneyama, Toyonaka, Osaka, 560-8552, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakoda</LastName><ForeName>Saburo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Organic Clinic, 3-1-57 Honmachi, Toyonaka, Osaka, 560-0021, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Med Case Rep</MedlineTA><NlmUniqueID>101293382</NlmUniqueID><ISSNLinking>1752-1947</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010789" MajorTopicYN="N">Phototherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062706" MajorTopicYN="N">Prodromal Symptoms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007319" MajorTopicYN="N">Sleep Initiation and Maintenance Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002940" MajorTopicYN="N">Circadian Rhythm</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Circadian</Keyword><Keyword MajorTopicYN="N">Depression</Keyword><Keyword MajorTopicYN="N">Fatigue</Keyword><Keyword MajorTopicYN="N">Insomnia</Keyword><Keyword MajorTopicYN="N">Light treatment</Keyword><Keyword MajorTopicYN="N">Long-COVID</Keyword><Keyword MajorTopicYN="N">Prodromal Parkinson’s disease</Keyword><Keyword MajorTopicYN="N">Sleep</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39438926</ArticleId><ArticleId IdType="doi">10.1186/s13256-024-04812-9</ArticleId><ArticleId IdType="pii">10.1186/s13256-024-04812-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bloem B, Okun M, Klein C. Parkinson’s disease. Lancet. 2021;397(10291):2284–303.</Citation><ArticleIdList><ArticleId IdType="pubmed">33848468</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(21)00218-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantovani S, Smith S, Gordon R, et al. An overview of sleep and circadian dysfunction in Parkinson’s disease. J Sleep Res. 2018;27(3): e12673.</Citation><ArticleIdList><ArticleId IdType="pubmed">29493044</ArticleId><ArticleId IdType="doi">10.1111/jsr.12673</ArticleId></ArticleIdList></Reference><Reference><Citation>Fifel K, De Boer T. The circadian system in Parkinson’s disease, multiple systems atrophy and progressive Supranuclear palsy. Handb Clin Neurol. 2021;179:301–13.</Citation><ArticleIdList><ArticleId IdType="pubmed">34225971</ArticleId><ArticleId IdType="doi">10.1016/B978-0-12-819975-6.00019-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Chan L, Chao Y, et al. Parkinson’s disease following COVID-19: causal link or chance occurrence? J Transl Med. 2020;18:493.</Citation><ArticleIdList><ArticleId IdType="pubmed">33375935</ArticleId><ArticleId IdType="pmc">7770740</ArticleId><ArticleId IdType="doi">10.1186/s12967-020-02670-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Fifel K, Videnovic A. Chronotherapies for Parkinson’s disease. Prog Neurobiol. 2019;174:16–27.</Citation><ArticleIdList><ArticleId IdType="pubmed">30658126</ArticleId><ArticleId IdType="pmc">6377295</ArticleId><ArticleId IdType="doi">10.1016/j.pneurobio.2019.01.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Willis G. Parkinson’s disease as a neuroendocrine disorder of circadian function: dopamine–melatonin imbalance and the visual system in the genesis and progression of the degenerative process. Rev Neurosci. 2008;19(4–5):245–316.</Citation><ArticleIdList><ArticleId IdType="pubmed">19145986</ArticleId></ArticleIdList></Reference><Reference><Citation>Fifel K, Videnovic A. Light therapy in Parkinson’s disease: towards mechanism-based protocols. Trends Neurosci. 2018;41(5):252–4.</Citation><ArticleIdList><ArticleId IdType="pubmed">29588060</ArticleId><ArticleId IdType="pmc">5924622</ArticleId><ArticleId IdType="doi">10.1016/j.tins.2018.03.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Ting S, Zhuang X. COVID-19, circadian rhythms and sleep: from virology to chronobiology. Interface Focus. 2021;11(6):20210043.</Citation><ArticleIdList><ArticleId IdType="pubmed">34956600</ArticleId><ArticleId IdType="pmc">8504895</ArticleId><ArticleId IdType="doi">10.1098/rsfs.2021.0043</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewy A, Ahmed S, Jackson J, et al. International society of chronobiology: melatonin shifts human circadian rhythms according to a phase-response curve. Chronobiol Int. 1992;9(5):380–92.</Citation><ArticleIdList><ArticleId IdType="pubmed">1394610</ArticleId><ArticleId IdType="doi">10.3109/07420529209064550</ArticleId></ArticleIdList></Reference><Reference><Citation>Willis G, Boda J, Freelance C. Polychromatic light exposure as a therapeutic in the treatment and management of Parkinson’s disease: a controlled exploratory trial. Front Neurol. 2018;9:741.</Citation><ArticleIdList><ArticleId IdType="pubmed">30778331</ArticleId><ArticleId IdType="pmc">6156259</ArticleId><ArticleId IdType="doi">10.3389/fneur.2018.00741</ArticleId></ArticleIdList></Reference><Reference><Citation>Willis G, Armstrong S. Fine-tuning the circadian system with light treatment for Parkinson’s disease: an in-depth critical review. Rev Neurosci. 2023;35(1):57–84.</Citation><ArticleIdList><ArticleId IdType="pubmed">37609845</ArticleId><ArticleId IdType="doi">10.1515/revneuro-2023-0026</ArticleId></ArticleIdList></Reference><Reference><Citation>Khatoon F, Prasad K, Kumar V. COVID-19 associated nervous system malfunctions. Sleep Med. 2022;91:231–6.</Citation><ArticleIdList><ArticleId IdType="pubmed">34321155</ArticleId><ArticleId IdType="doi">10.1016/j.sleep.2021.07.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehandru S, Merad M. Pathological sequelae of long-haul COVID. Nat Immunol. 2022;23(2):194–202.</Citation><ArticleIdList><ArticleId IdType="pubmed">35105985</ArticleId><ArticleId IdType="pmc">9127978</ArticleId><ArticleId IdType="doi">10.1038/s41590-021-01104-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Niu L, Liu X, et al. Recent progress in non-motor features of Parkinson’s disease with a focus on circadian rhythm dysregulation. Neurosci Bull. 2021;37(7):1010–24.</Citation><ArticleIdList><ArticleId IdType="pubmed">34128188</ArticleId><ArticleId IdType="pmc">8275711</ArticleId><ArticleId IdType="doi">10.1007/s12264-021-00711-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Beauchamp L, Finkelstein D, Bush A, et al. Parkinsonism as a third wave of the COVID-19 pandemic. J Park Res. 2020;10(4):1343–53.</Citation></Reference><Reference><Citation>Hood S, Amir S. The aging clock: circadian rhythms and later life. J Clin Invest. 2017;127(2):437–46.</Citation><ArticleIdList><ArticleId IdType="pubmed">28145903</ArticleId><ArticleId IdType="pmc">5272178</ArticleId><ArticleId IdType="doi">10.1172/JCI90328</ArticleId></ArticleIdList></Reference><Reference><Citation>Cartella S, Terranova C, Rizzo V, et al. COVID-19 and Parkinson’s disease: an overview. J Neurol. 2021;268(12):4415–21.</Citation><ArticleIdList><ArticleId IdType="pubmed">34313818</ArticleId><ArticleId IdType="pmc">8313415</ArticleId><ArticleId IdType="doi">10.1007/s00415-021-10721-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Leng Y, Blackwell T, Cawthon P, et al. Association of circadian abnormalities in older adults with an increased risk of developing Parkinson disease. JAMA Neurol. 2020;77(10):1270–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">32539075</ArticleId><ArticleId IdType="pmc">7296450</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2020.1623</ArticleId></ArticleIdList></Reference><Reference><Citation>Willis G, Moore C, Armstrong S. A historical justification for and retrospective analysis of the systematic application of light therapy in Parkinson’s disease. Rev Neurosci. 2012;23(2):199–226.</Citation><ArticleIdList><ArticleId IdType="pubmed">22499678</ArticleId><ArticleId IdType="doi">10.1515/revneuro-2011-0072</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewy A, Sack R, Singer C. Immediate and delayed effects of bright light on human melatonin production: shifting “dawn” and “dusk” shifts the dime light melatonin onset (DLMO). Ann N Y Acad Sci. 1985;453:253–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">3865585</ArticleId><ArticleId IdType="doi">10.1111/j.1749-6632.1985.tb11815.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewy A, Rough J, Songer J, et al. The phase shift hypothesis for the circadian component of winter depression. Dialogues Clin Neurosci. 2007;9(3):291–300.</Citation><ArticleIdList><ArticleId IdType="pubmed">17969866</ArticleId><ArticleId IdType="pmc">3202495</ArticleId><ArticleId IdType="doi">10.31887/DCNS.2007.9.3/alewy</ArticleId></ArticleIdList></Reference><Reference><Citation>Willis G. Common circadian features of the 1919 and COVID19 pandemics: the long-COVID and prodromal Parkinson’s parallel. 2023 (Submitted 2023).</Citation></Reference><Reference><Citation>Willis G, Turner J. Primary and secondary features of Parkinson’s disease improve with strategic exposure to bright light: a case series study. Chronobiol Int. 2007;24(3):521–37.</Citation><ArticleIdList><ArticleId IdType="pubmed">17612949</ArticleId><ArticleId IdType="doi">10.1080/07420520701420717</ArticleId></ArticleIdList></Reference><Reference><Citation>Artemenko AR, Leven L. The phototherapy for Parkinson’s patients. Zh Nevrol Psikhiatr Im SS Korsakova. 1996;96:63–6.</Citation></Reference><Reference><Citation>Martino K, Freelance C, Willis G. The effect of light exposure on insomnia and nocturnal movement in Parkinson’s disease: an open label, retrospective, longitudinal study. Sleep Med. 2018;44:24–31.</Citation><ArticleIdList><ArticleId IdType="pubmed">29530365</ArticleId><ArticleId IdType="doi">10.1016/j.sleep.2018.01.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Paus S, Schmitz-Hübsch T, Wüllner U, et al. Bright light therapy in Parkinson’s disease: a pilot study. Mov Disord. 2007;22(10):1495–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17516492</ArticleId><ArticleId IdType="doi">10.1002/mds.21542</ArticleId></ArticleIdList></Reference><Reference><Citation>Videnovic A, Klerman E, Wang W, et al. Timed light therapy for sleep and daytime sleepiness associated with Parkinson’s disease: a randomised clinical trial. JAMA Neurol. 2017;74(4):411–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">28241159</ArticleId><ArticleId IdType="pmc">5470356</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2016.5192</ArticleId></ArticleIdList></Reference><Reference><Citation>Massey D, Mitsuaki S, Baker AD, et al. Characterisation of internal tremors and vibration symptoms. BMJ Open. 2023;13(12): e077389.</Citation><ArticleIdList><ArticleId IdType="pubmed">38154880</ArticleId><ArticleId IdType="pmc">10759066</ArticleId><ArticleId IdType="doi">10.1136/bmjopen-2023-077389</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutten S, Vriend C, Smit J, et al. Bright light therapy for depression in Parkinson’s disease: a randomised controlled trial. Neurology. 2019;92(11):e1145–56.</Citation><ArticleIdList><ArticleId IdType="pubmed">30770426</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000007090</ArticleId></ArticleIdList></Reference><Reference><Citation>Makhoul K, Jankovic J. Parkinson’s disease after COVID-19. J Neurol Sci. 2021;422: 117331.</Citation><ArticleIdList><ArticleId IdType="pubmed">33540185</ArticleId><ArticleId IdType="pmc">9755718</ArticleId><ArticleId IdType="doi">10.1016/j.jns.2021.117331</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarifkar P, Peinkhofer P, Benros M, et al. Frequency of neurological diseases after COVID-19, Influenza A/B and bacterial pneumonia. Front Neurol. 2022;13: 904796.</Citation><ArticleIdList><ArticleId IdType="pubmed">35812108</ArticleId><ArticleId IdType="pmc">9259944</ArticleId><ArticleId IdType="doi">10.3389/fneur.2022.904796</ArticleId></ArticleIdList></Reference><Reference><Citation>Sulser D, Antonini A, Leta V, et al. COVID-19 and possible links with Parkinson’s disease and parkinsonism: from bench to bedside. NPJ Park Dis. 2020;6(1):18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41531-020-00123-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacks O. Awakenings. London: Picador; 1973.</Citation></Reference><Reference><Citation>Musiek E, Holtzman D. Mechanisms linking circadian clocks, sleep, and neurodegeneration. Science. 2016;354(6315):1004–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">27885006</ArticleId><ArticleId IdType="pmc">5219881</ArticleId><ArticleId IdType="doi">10.1126/science.aah4968</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Prettner K, Kuhn M, et al. Climate and the spread of COVID-19. Sci Rep. 2021;11(1):9042.</Citation><ArticleIdList><ArticleId IdType="pubmed">33907202</ArticleId><ArticleId IdType="pmc">8079387</ArticleId><ArticleId IdType="doi">10.1038/s41598-021-87692-z</ArticleId></ArticleIdList></Reference><Reference><Citation>de Pedro Cuesta J. Studies of the prevalence of paralysis agitans by tracer methodology. Acta Neurol Scand Suppl. 1987;112:1–106.</Citation><ArticleIdList><ArticleId IdType="pubmed">3303809</ArticleId></ArticleIdList></Reference><Reference><Citation>de Pedro CJ, Stawiarz L. Parkinson’s disease incidence: magnitude, comparability, time trends. Acta Neurol Scand. 1991;84:382–8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0404.1991.tb04974.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H, Schernhammer E, Schwarzchild M, et al. A prospective study of night shift work, sleep duration and risk of Parkinson’s disease. Am J Epidemiol. 2021;163:726–30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwj096</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakano T, Chiang K, Chen C, et al. Sunlight exposure and phototherapy: perspectives for healthy aging in an era of COVID-19. Int J Environ Res Public Health. 2021;18(20):10950.</Citation><ArticleIdList><ArticleId IdType="pubmed">34682694</ArticleId><ArticleId IdType="pmc">8535353</ArticleId><ArticleId IdType="doi">10.3390/ijerph182010950</ArticleId></ArticleIdList></Reference><Reference><Citation>Golombek D, Pandi-Perumal S, Rosenstein R, et al. Dysregulated dark/light cycle impairs sleep and delays the recovery of patients in intensive care units: a call for action for COVID-19 treatment. Chronobiol Int. 2022;39(7):903–6.</Citation><ArticleIdList><ArticleId IdType="pubmed">35491759</ArticleId><ArticleId IdType="doi">10.1080/07420528.2022.2056477</ArticleId></ArticleIdList></Reference><Reference><Citation>Monoz-Gonzalez C, Ruiz-Jaramillo J, Cuerdo-Vilches T, et al. Natural lighting in historic houses during times of pandemic. The case of housing in the Mediterranean climate. Int J Environ Res Public Health. 2021;18(14):7264.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph18147264</ArticleId></ArticleIdList></Reference><Reference><Citation>Megna M, Marasca C, Fabbrocini G. Ultraviolet radiation, vitamin D and COVID-19. Ital J Dermatol Venerol. 2021;156(3):366–73.</Citation><ArticleIdList><ArticleId IdType="pubmed">33913665</ArticleId></ArticleIdList></Reference><Reference><Citation>Soheilifar S, Fathi H, Naghdi N. Photobiomodulation therapy as a high potential treatment modality for COVID-19. Lasers Med Sci. 2021;36(5):935–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">33241526</ArticleId><ArticleId IdType="doi">10.1007/s10103-020-03206-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabino C, Ball A, Baptista M, et al. Light-based technologies for management of COVID-19 pandemic crisis. J Photochem Photobiol B. 2020;212: 111999.</Citation><ArticleIdList><ArticleId IdType="pubmed">32855026</ArticleId><ArticleId IdType="pmc">7435279</ArticleId><ArticleId IdType="doi">10.1016/j.jphotobiol.2020.111999</ArticleId></ArticleIdList></Reference><Reference><Citation>Leta V, Boura I, van Wamelen D, et al. Covid-19 and Parkinson’s disease: acute clinical implications, long-COVID and post-COVID-19 parkinsonism. Int Rev Neurobiol. 2022;165:63–89.</Citation><ArticleIdList><ArticleId IdType="pubmed">36208907</ArticleId><ArticleId IdType="pmc">9357514</ArticleId><ArticleId IdType="doi">10.1016/bs.irn.2022.04.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Rota R, Boura I, Wan Y, et al. Spotlight on non-motor symptoms and COVID-19. Int Rev Neurosci. 2022;165:103–33.</Citation></Reference><Reference><Citation>Endo T, Matsumura R, Tokuda I, et al. Bright light improves sleep in patients with Parkinson’s disease: possible role of circadian restoration. Sci Rep. 2020;10(1):7982.</Citation><ArticleIdList><ArticleId IdType="pubmed">32409683</ArticleId><ArticleId IdType="pmc">7224174</ArticleId><ArticleId IdType="doi">10.1038/s41598-020-64645-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Fertl E, Auff E, Dopplebauer A, et al. Circadian secretion pattern of melatonin in Parkinson’s disease. J Neural Transm. 1991;3:41–7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02251135</ArticleId></ArticleIdList></Reference><Reference><Citation>Wescott D, Wallace M, Hasler B, et al. Sleep and circadian rhythm profiles in seasonal depression. Psychiatr Res. 2022;156:114–21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpsychires.2022.10.019</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim R, Wambier C, Goren A. Are night shift workers at an increased risk for COVID-19? Med Hypothesis. 2020;144: 110147.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2020.110147</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricter K, Kellner S, Hillemacher T, et al. Sleep quality and COVID-19 outcomes: the evidence-based lessons in the framework of predictive, preventive and personalised (3p) medicine. EPMA J. 2021;12(2):221–41.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13167-021-00245-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Pillai J, Bonner-Jackson A, Floden D, et al. Lack of accurate self-appraisal is equally likely in MCI from Parkinson’s disease and Alzheimer’s disease. Mov Disord Clin Prac. 2018;5(3):283–9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mdc3.12606</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown G, Pandi-Perumal S, Pupko H, et al. Melatonin as an add-on treatment of COVID-19 infection: current status. Diseases. 2021;9(3):64.</Citation><ArticleIdList><ArticleId IdType="pubmed">34562971</ArticleId><ArticleId IdType="pmc">8482145</ArticleId><ArticleId IdType="doi">10.3390/diseases9030064</ArticleId></ArticleIdList></Reference><Reference><Citation>Brusco L, Cruz P, Cangas A, et al. Efficacy of melatonin in non-intensive care unit patients with COVID-19 pneumonia and sleep dysregulation. Melatonin Res. 2021;4(1):173–88.</Citation><ArticleIdList><ArticleId IdType="doi">10.32794/mr11250089</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardinali D, Brown G, Pandi-Perumal S. Can melatonin be a potential “silver bullet” in treating COVID-19 patients? Diseases. 2020;8(4):44.</Citation><ArticleIdList><ArticleId IdType="pubmed">33256258</ArticleId><ArticleId IdType="pmc">7709121</ArticleId><ArticleId IdType="doi">10.3390/diseases8040044</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong AC, Devason A, Umana I, et al. Serotonin reduction in post-acute sequelae of viral infection. Cell. 2023;186:4851–67.</Citation><ArticleIdList><ArticleId IdType="pubmed">37848036</ArticleId><ArticleId IdType="pmc">11227373</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2023.09.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Krashner N, Cornelius J. L-dopa for post-encephalitic parkinsonism. Br Med J. 1970;4(5733):496.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.4.5733.496</ArticleId></ArticleIdList></Reference><Reference><Citation>Rus C, de Vries B, de Vries E, et al. Treatment of 95 post-COVID patients with SSRIs. Sci Rep. 2023;13:18599.</Citation><ArticleIdList><ArticleId IdType="pubmed">37919310</ArticleId><ArticleId IdType="pmc">10622561</ArticleId><ArticleId IdType="doi">10.1038/s41598-023-45072-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Abreu G, Aguilar M, Covarrubias D, et al. Amantadine as a drug to mitigate the effect of COVID 19. Med Hypothesis. 2020;140: 109755.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2020.109755</ArticleId></ArticleIdList></Reference><Reference><Citation>Anwar F, Naqvi S, Al-Abbasi F, et al. Targeting COVID-19 in Parkinson’s patients: drugs repurposed. Curr Med Chem. 2021;28(12):2392–408.</Citation><ArticleIdList><ArticleId IdType="pubmed">32881656</ArticleId><ArticleId IdType="doi">10.2174/0929867327666200903115138</ArticleId></ArticleIdList></Reference><Reference><Citation>an het Rot M, Benkelfat C, Boivin D, et al. Bright light exposure during acute tryptophan depletion prevents a lowering of mood in mildly seasonal women. Eur Neuropsychopharmacol. 2007;18(1):14–23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.euroneuro.2007.05.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewy A, Emens J, Sack R, et al. Low, but not high, doses of melatonin entrained a free-running blind person with a long circadian period. Chronobiol Int. 2002;19(3):649–58.</Citation><ArticleIdList><ArticleId IdType="pubmed">12069043</ArticleId><ArticleId IdType="doi">10.1081/CBI-120004546</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin L, Du Y, Yuan S, et al. Serum melatonin is an alternative index of Parkinson’s disease severity. Brain Res. 2014;1547:43–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">24384141</ArticleId><ArticleId IdType="doi">10.1016/j.brainres.2013.12.021</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng T, Zheng Z, Tiu T, et al. Contralateral retinal dopamine decrease and melatonin increase in progression of hemi-Parkinsonian rat. Neurochem Res. 2012;37(5):1050–6.</Citation><ArticleIdList><ArticleId IdType="pubmed">22252727</ArticleId><ArticleId IdType="doi">10.1007/s11064-012-0706-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Willis G, Robertson A. Recovery of experimental Parkinson’s disease with the melatonin analogues ML-23 and S-20928 in a chronic, bilateral 6-OHDA model: a new mechanism involving antagonism of the melatonin receptor. Pharmacol Biochem Behav. 2004;79(3):413–29.</Citation><ArticleIdList><ArticleId IdType="pubmed">15582013</ArticleId><ArticleId IdType="doi">10.1016/j.pbb.2004.08.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Willis G, Robertson A. Recovery of experimental Parkinson’s disease in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine treated marmoset with the melatonin analogue ML-23. Pharmacol Biochem Behav. 2005;80(1):9–26.</Citation><ArticleIdList><ArticleId IdType="pubmed">15652376</ArticleId><ArticleId IdType="doi">10.1016/j.pbb.2004.10.022</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacks O, Kohl M, Schwartz W, et al. Side-effects of L-dopa in post-encephalic parkinsonism. Lancet. 1970;1(7654):1006.</Citation><ArticleIdList><ArticleId IdType="pubmed">4191927</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(70)91137-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacks O, Messeloff C, Schwartz W. Long-term effects of levodopa in the severely disabled patient. JAMA. 1970;213(13):2270.</Citation><ArticleIdList><ArticleId IdType="pubmed">5468938</ArticleId><ArticleId IdType="doi">10.1001/jama.1970.03170390060017</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahlknecht P, Seppi K, Poewe W. The concept of prodromal Parkinson’s disease. J Park Dis. 2015;5:681–97.</Citation></Reference><Reference><Citation>Li T, Cheng C, Jai, et al. Peripheral clock system abnormalities in patients with Parkinson’s disease. Front Aging Neurosci. 2021;13: 736026.</Citation><ArticleIdList><ArticleId IdType="pubmed">34658839</ArticleId><ArticleId IdType="pmc">8519399</ArticleId><ArticleId IdType="doi">10.3389/fnagi.2021.736026</ArticleId></ArticleIdList></Reference><Reference><Citation>Naik R, Avula S, Palleti S, et al. From emergence to endemicity: a comprehensive review of COVID-19. Cureus. 2023;15(10): e48046.</Citation><ArticleIdList><ArticleId IdType="pubmed">37916248</ArticleId><ArticleId IdType="pmc">10617653</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>